Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …
hopeful evidence about dementia prevention, intervention, and care. As people live longer …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …
patients who could benefit from these treatments becomes critical. In this study, we …
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
M Schöll, IMW Verberk, M Del Campo… - The Lancet Healthy …, 2024 - thelancet.com
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
Blood biomarkers to detect Alzheimer disease in primary care and secondary care
S Palmqvist, P Tideman, N Mattsson-Carlgren… - JAMA, 2024 - jamanetwork.com
Importance An accurate blood test for Alzheimer disease (AD) could streamline the
diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically …
diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically …
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
J Arranz, N Zhu, S Rubio-Guerra… - Alzheimer's Research & …, 2024 - Springer
Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
N Warmenhoven, G Salvadó, S Janelidze… - Brain, 2024 - academic.oup.com
Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising
biomarker for reliable detection of Alzheimer's disease pathology. Various p-tau217 assays …
biomarker for reliable detection of Alzheimer's disease pathology. Various p-tau217 assays …
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Biomarkers have been instrumental in population selection and disease monitoring in
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …
clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of …